We are a company specializing in innovative solutions in medical technology and biotechnology. Our team is interdisciplinary: the shareholders come from the fields of medicine, development and the start-up scene.
We combine expertise
with a keen eye for market potential.
Our mission
SurgMark is committed to developing innovative solutions for the diagnosis and treatment of breast cancer and other tumors. Through our latest tool, SchurSign®, we integrate expertise from both breast surgery and biomaterial research.
We are more than the sum of its many years of experience
Dr. Christine König, PhD
CEO, experienced founder and CEO in the life sciences industry, over 20 years experience as serial entrepreneur and international top management consultant.
Dr. Thomas Freier, PhD
Sen. VP, product development and quality assurance, chemist and serial entrepreneur in the biomaterials- and medical sciences.
Dr. Rivelino Montenegro, PhD
Sen. VP, regulatory affairs and chemistry, multiple times entrepreneur in the medical field and experienced chemist in materials science.
Dr. Frank Schure, MD
CCO, gynecologist and obstetrician, Senior Surgeon in breast and oncology, specialist for ultrasound guided surgery and edge of specimen ultrasound.
Dr. Peter A. Meier, MD, MBA
CMO, entrepreneur and advisor with over 20 yrs. senior management and business development experience in the medical device industry.